ABVD versus BEACOPP for Hodgkin's Lymphoma
To the Editor: Viviani and colleagues (July 21 issue) 1 compared the ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) with an escalated BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, with higherthan-standard doses of etoposide, doxorubicin, and cyclophosphamide) for initial treatment in patients with advanced-stage Hodgkin's lymphoma. They concluded that these initial treatment strategies had equivalent rates of long-term overall survival. This conclusion contradicts that of the HD9 study by Diehl and colleagues, which showed superior overall survival with the BEACOPP regimen as compared with a COPP-ABVD regimen. 2, 3 We are concerned about the emphasis on overall survival (a secondary end point) in a study designed to examine freedom from first progression. The HD9 study was larger than the current study (727 patients vs. 331 patients), had a longer follow-up period (median, 111 months vs. 61 months), and had numerically higher success rates in salvage treatment after ABVD failure (overall survival >50% in HD9 vs. durable complete responses of 33% in the study by Viviani and colleagues). 1,3 Using the hazard ratio and P value provided in their study, we estimate the 95% confidence interval for the hazard ratio for overall survival to be 0.39 to 1.45. This confidence interval is too wide to draw conclusions about overall survival at this time. Until more mature follow-up data are available, the analysis cannot be interpreted to support the claimed equivalence in overall survival.
